Cargando…
Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019
WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236642/ https://www.ncbi.nlm.nih.gov/pubmed/37274767 http://dx.doi.org/10.46234/ccdcw2023.083 |
_version_ | 1785052982200500224 |
---|---|
author | Qin, Min Wang, Liying Wang, Ying Wang, Xu Lei, Jiaxi Cheng, Xixi Feng, Yu Hou, Yanyan Wang, Qian Xue, Chuizhao Gavotte, Laurent Frutos, Roger |
author_facet | Qin, Min Wang, Liying Wang, Ying Wang, Xu Lei, Jiaxi Cheng, Xixi Feng, Yu Hou, Yanyan Wang, Qian Xue, Chuizhao Gavotte, Laurent Frutos, Roger |
author_sort | Qin, Min |
collection | PubMed |
description | WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS ADDED BY THIS REPORT? This study reviewed the medical records of 899 patients who underwent albendazole treatment across 10 endemic counties. Out of 634 evaluable patient files, the proportion of patients with a ratio of actual follow-up and reexamination times to theoretical follow-up and reexamination times ≥0.8 were both low (21.92% and 23.19%, respectively). WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES? This study identified weaknesses and specific issues in patient management and proposed feasible recommendations to enhance patient file documentation, follow-up, and reexamination. |
format | Online Article Text |
id | pubmed-10236642 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-102366422023-06-03 Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 Qin, Min Wang, Liying Wang, Ying Wang, Xu Lei, Jiaxi Cheng, Xixi Feng, Yu Hou, Yanyan Wang, Qian Xue, Chuizhao Gavotte, Laurent Frutos, Roger China CDC Wkly Preplanned Studies WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? In China, patients with echinococcosis receive complimentary healthcare services, such as medical treatment, diagnostic examinations, and follow-up care. Despite this, no studies have been conducted to assess the quality of patient management to date. WHAT IS ADDED BY THIS REPORT? This study reviewed the medical records of 899 patients who underwent albendazole treatment across 10 endemic counties. Out of 634 evaluable patient files, the proportion of patients with a ratio of actual follow-up and reexamination times to theoretical follow-up and reexamination times ≥0.8 were both low (21.92% and 23.19%, respectively). WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICES? This study identified weaknesses and specific issues in patient management and proposed feasible recommendations to enhance patient file documentation, follow-up, and reexamination. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023-05-19 /pmc/articles/PMC10236642/ /pubmed/37274767 http://dx.doi.org/10.46234/ccdcw2023.083 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2023 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/) |
spellingShingle | Preplanned Studies Qin, Min Wang, Liying Wang, Ying Wang, Xu Lei, Jiaxi Cheng, Xixi Feng, Yu Hou, Yanyan Wang, Qian Xue, Chuizhao Gavotte, Laurent Frutos, Roger Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title | Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title_full | Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title_fullStr | Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title_full_unstemmed | Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title_short | Investigation on the Management for Patients with Echinococcosis Treated with Albendazole — Three PLADs, China, 2019 |
title_sort | investigation on the management for patients with echinococcosis treated with albendazole — three plads, china, 2019 |
topic | Preplanned Studies |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10236642/ https://www.ncbi.nlm.nih.gov/pubmed/37274767 http://dx.doi.org/10.46234/ccdcw2023.083 |
work_keys_str_mv | AT qinmin investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT wangliying investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT wangying investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT wangxu investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT leijiaxi investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT chengxixi investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT fengyu investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT houyanyan investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT wangqian investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT xuechuizhao investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT gavottelaurent investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 AT frutosroger investigationonthemanagementforpatientswithechinococcosistreatedwithalbendazolethreepladschina2019 |